Versatope Receives Grants to Support Malaria Vaccine Development
LOWELL, Mass., June 28, 2024 – Versatope Therapeutics Incorporated, a biotechnology company developing vaccines and immuno-therapeutics announced today it has received a Phase 2 Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health for up to $3 million over three years. Versatope will use the grant to develop a bi-specific malaria vaccine using a target that blocks both the initial malaria infection and transmission. The novel, dual-acting vaccine may offer a more robust approach than a single acting vaccine.
Versatope Expands Scientific Advisory Board with Dr. Jim Tartaglia and Board of Directors with Dr. Sam Rasty and Edward Jordan
LOWELL, Mass., Mar. 10, 2025 Versatope announced today that Edward P. Jordan, MBA, and Dr. Sam Rasty, have joined the company’s Board of Directors to support commercial strategy and business development efforts. Separately, Dr. James Tartaglia, an internationally recognized vaccine R&D leader, joined the Scientific Advisory Board to contribute his expertise in vaccine development and life cycle management.
Versatope Launches Clinical Development Team for VT-105, a Pan-influenza A Vaccine Candidate
LOWELL, Mass., Sept. 11, 2024 Versatope Therapeutics Incorporated announced today their new Chief Medical Officer, Dr. M.P. Anza Mammen, MD and the addition of their Chairman of the Scientific Advisory Board, Dr. Robert B. Belshe.
Advancing Vaccines with Extracellular Vesicles
September 27, 2022 Dr. Christopher Locher, Versatope Therapeutics, explains why bacterial extracellular vesicles are ideally suited for recombinant vaccines because target antigens can be expressed as fusion proteins and targeted to the lumen, membrane or surface of the vesicles.
LOWELL, Mass., Oct. 14, 2021 Versatope announced today that Dr. Drew Weissman, a leading mRNA vaccine expert, joined their Scientific Advisory Board. Separately, Dr. James Kuo and Jeremy Gowler joined the company's Board of Directors to diversify their pipeline and expand their business development activities.
Clostridium difficile bacteria, 3D illustration. Photo: Kateryna Kon / Shutterstock
May 6, 2020 - Versatope featured on Boston 25 News in a story featuring companies at UMass Lowell's M2D2 who are working on innovative solutions for COVID-19.
MORE NEWS and ARTICLES
-
Versatope Names New Members to its Board of Directors
Versatope announced that two new Board of Directors, Dr. Salim Yazji and Ms. Brenda McCabe joined the company to support the company’s strategy and management.
-
Versatope Therapeutics Wins First Prize at the Massachusetts Life Science Innovators (MALSI) Conference
Versatope Therapeutics received the first prize at the 11th Massachusetts Life Science Innovators (MALSI) conference
-
Versatope leverages resources at U Mass Lowell M2D2
Versatope delivers drugs and vaccines from genetically engineered probiotics. Article from the Lowell Sun newspaper.
-
Versatope takes 2nd Place in the 200K M2D2 Competition
The 2018 200K M2D2 competition winners were announced on April 10th at Mintz Levin in Boston. Versatope took the second place prize. Congratulations to the team that worked hard to get us there.
-
Revolutionizing Drug Delivery
Advancing drug delivery: Convergence and Medical Devices/Drugs Symposium
-
Versatope Therapeutics, Inc. selected as a Johnson & Johnson Innovation, JLABS resident company
Versatope was selected as a resident company by Johnson & Johnson Innovation, JLABS at the M2D2 incubator in Lowell, Massachusetts
-
M2D2 200K Finalist in 2018
Versatope selected as a finalist in the 200K M2D2 Challenge
-
Versatope Therapeutics Launches R&D Effort at M2D2
Versatope Therapeutics celebrated the launch of its new laboratory space at the Massachusetts Medical Device Development Center (M2D2) incubator at the University of Massachusetts Lowell.
-
Winner of Pharma Directions challenge
Versatope won the the 1st Annual Massachusetts Jump Start Grant Challenge sponsored by PharmaDirections, in cooperation with MassBio.
-
New Startups Debut at MassCONNECT® Showcase, Bayer & Nutter Sponsor Mentorship Program CycleList Item 1
This MassCONNECT® class includes entrepreneurs working to fight diabetes, discover drugs by screening in living animal models, revolutionize intravascular therapeutic embolization and deliver immunity with designer recombinant nanoparticles
-
MassChallenge Boston Announces 2017 CohortList Item 2
128 high-impact companies to access global network of support and resources in Boston
-
Cornell Chronicle: A new kind of influenza vaccine: One shot might do the trickList Item 3
A seasonal flu shot is a bit like a local weather forecast: Based on the conditions elsewhere and the direction of the prevailing wind, a meteorologist can give the public a pretty good idea of what to expect in the near future. Experts who track influenza’s intercontinental travels basically do the same thing.
-
Cornell Chronicle: Sugar-coated vesicles prove effective in laboratory tests on deadly pathogensList Item 4
For 30 years, conjugate vaccines have proven effective in reducing the incidence of disease caused by bacterial pathogens, including Haemophilus influenzae type b (Hib), a form of bacterial meningitis that kills thousands of infants annually in the underdeveloped world.
-
Cornell Chronicle: Engineered E. coli vesicles act as vaccine deliverers
Mention E. coli and what pops into most people’s heads are bacteria, tainted food, a rush to the hospital – basically, fear. “E. coli gets a bad rap – and rightfully so,” said Matthew DeLisa, the William L. Lewis Professor of Engineering.